Archives

  • 2026-10
  • 2026-09
  • 2026-08
  • 2026-07
  • 2026-06
  • 2026-05
  • 2026-04
  • 2026-03
  • 2026-02
  • 2026-01
  • 2025-12
  • 2025-11
  • 2025-10
  • 2025-09
  • 2025-03
  • 2025-02
  • 2025-01
  • 2024-12
  • 2024-11
  • 2024-10
  • 2024-09
  • 2024-08
  • 2024-07
  • 2024-06
  • 2024-05
  • 2024-04
  • 2024-03
  • 2024-02
  • 2024-01
  • 2023-12
  • 2023-11
  • 2023-10
  • 2023-09
  • 2023-08
  • 2023-07
  • 2023-06
  • 2023-05
  • 2023-04
  • 2023-03
  • 2023-02
  • 2023-01
  • 2022-12
  • 2022-11
  • 2022-10
  • 2022-09
  • 2022-08
  • 2022-07
  • 2022-06
  • 2022-05
  • 2022-04
  • 2022-03
  • 2022-02
  • 2022-01

    • N1-Methyl-Pseudouridine-5'-Triphosphate: Modified Nucleos...

    2026-02-20

    N1-Methyl-Pseudouridine-5'-Triphosphate: Modified Nucleoside Triphosphate for RNA Synthesis and Stability

    Executive Summary: N1-Methyl-Pseudouridine-5'-Triphosphate (N1-Methylpseudo-UTP) is a chemically modified nucleoside triphosphate in which the N1 position of pseudouridine is methylated, resulting in enhanced RNA stability and reduced immunogenicity (McIntyre et al., 2025). This reagent is incorporated into RNA during in vitro transcription to improve translational output, especially in mRNA vaccine development (internal). The product, supplied by APExBIO (SKU B8049), is ≥90% pure (AX-HPLC) and must be stored at -20°C or below (product page). Its use has advanced research on RNA-protein interactions, RNA secondary structure, and precise genome engineering (internal). Adoption of N1-Methylpseudo-UTP has become pivotal for robust and reproducible RNA-based workflows.

    Biological Rationale

    N1-Methyl-Pseudouridine-5'-Triphosphate is a synthetic nucleotide analog specifically designed to address limitations of canonical uridine triphosphate in RNA synthesis. The methyl group at the N1 position of pseudouridine confers increased chemical and enzymatic stability to RNA transcripts (McIntyre et al., 2025). This modification reduces innate immune activation, a key challenge in therapeutic RNA applications, by minimizing recognition by pattern recognition receptors (internal). Improved stability and reduced immunogenicity directly benefit mRNA vaccine design and RNA-protein interaction studies. The molecule's structure also supports maintenance of desired RNA secondary structures, crucial for translation efficiency and functional studies (internal).

    Mechanism of Action of N1-Methyl-Pseudouridine-5'-Triphosphate

    N1-Methylpseudo-UTP is enzymatically incorporated into RNA during in vitro transcription (IVT) using T7, SP6, or T3 RNA polymerases under standard reaction conditions (pH 7.5–8.0, 37°C, 2–4 hours). The methylation at position N1 of pseudouridine alters hydrogen bonding and base stacking, which stabilizes the RNA duplex and resists exonuclease-mediated degradation (McIntyre et al., 2025). This modification also reduces recognition by Toll-like receptors (TLR7/8), minimizing innate immune responses. When used in mRNA synthesis for vaccines, such as those targeting SARS-CoV-2, the modified nucleotide supports higher protein expression levels by promoting proper ribosomal engagement and decreasing mRNA decay (internal). The net effect is an RNA molecule with enhanced translational fidelity and biological half-life.

    Evidence & Benchmarks

    • N1-Methylpseudo-UTP incorporation increases RNA half-life by up to 2-fold compared to unmodified uridine in in vitro assays (McIntyre et al., DOI:10.1126/science.adz3121).
    • mRNA containing N1-Methylpseudo-UTP shows reduced TLR7/8 activation and lower type I interferon production in human dendritic cells (internal).
    • Transcripts generated with N1-Methylpseudo-UTP yield up to 3× higher protein expression in mammalian cell transfection models versus canonical UTP (see Fig. S2 in internal).
    • Purity of ≥90% (AX-HPLC) ensures reliable in vitro transcription and minimizes undesired byproducts (product page).
    • Optimized for mRNA vaccine and genome engineering workflows requiring high RNA integrity and reproducibility (internal).

    Applications, Limits & Misconceptions

    N1-Methylpseudo-UTP is widely utilized in:

    • mRNA vaccine development (e.g., COVID-19 mRNA vaccines), due to enhanced translation and reduced immunogenicity.
    • In vitro transcription protocols requiring high stability and low degradation rates.
    • RNA-protein interaction studies where RNA integrity is critical for reproducible binding assays.
    • Genome engineering approaches leveraging stabilized RNA intermediates (McIntyre et al., 2025).

    Compared to other modified nucleotides, N1-Methylpseudo-UTP specifically balances translational enhancement with immunogenicity reduction. For a deeper dive into protocols and troubleshooting, see this guide (which this article expands by providing mechanistic and clinical context).

    Common Pitfalls or Misconceptions

    • Misconception: N1-Methylpseudo-UTP can substitute for all uridine analogs in every system.
      Clarification: Its effects are context-dependent and may not generalize to non-eukaryotic translation systems.
    • Pitfall: Overuse can alter RNA secondary structure in unwanted ways, affecting ribozyme or aptamer function.
    • Misconception: N1-Methylpseudo-UTP eliminates immunogenicity entirely.
      Clarification: While it reduces innate immune activation, residual responses may still occur at high RNA doses.
    • Limitation: Storage above -20°C can degrade the nucleotide and decrease transcription yields (product page).
    • Misconception: All RNA polymerases incorporate the modified nucleotide with equal efficiency.
      Clarification: Some enzymes show reduced activity or fidelity with modified nucleotides. Empirical optimization is recommended.

    For more on workflow troubleshooting and efficiency, see this article (which this piece updates by integrating new peer-reviewed evidence and clinical translation benchmarks).

    Workflow Integration & Parameters

    N1-Methylpseudo-UTP is supplied as a ≥90% pure (AX-HPLC) sodium salt, typically at 100 mM in aqueous solution. Store at -20°C or below; avoid repeated freeze-thaw cycles. Recommended in vitro transcription conditions are 1–5 mM N1-Methylpseudo-UTP, 1x transcription buffer (pH 7.5–8.0), 37°C, and a reaction time of 2–4 hours. Substitution ratios (relative to UTP) vary from 25% to 100% depending on the desired effect on translation and immunogenicity. After transcription, standard DNase I digestion, LiCl or column purification, and QC by gel or HPLC are advised. The product is for research use only, not for diagnostic or therapeutic applications (product page).

    For comparative perspectives on RNA stability and genome engineering, see this review (which this article clarifies by summarizing current mechanistic insights and product-specific integration parameters).

    Conclusion & Outlook

    N1-Methyl-Pseudouridine-5'-Triphosphate is a key reagent for advanced RNA research and mRNA therapeutic development. Its unique molecular modification enhances RNA stability, translational efficiency, and reduces immunogenicity. These properties directly address challenges in RNA workflow reproducibility and therapeutic development. As genome engineering and mRNA vaccines advance, N1-Methylpseudo-UTP is expected to remain central to both research and translational applications. For product specifications and ordering, see the APExBIO product page.